Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
Importance: The pharmaceutical industry has made substantial investments in developing processes for sharing individual-participant data (IPD) from clinical trials. However, the utility and completeness of shared IPD and supporting documents must be evaluated to ensure the potential for scientific advancements from the data sharing ecosystem can be realized.
Objective: To assess the utility and completeness of IPD and supporting documents provided from industry-sponsored clinical trials.
Design, Setting, and Participants: From February 9, 2022, to February 9, 2023, 91 of 203 clinical trials supporting US Food and Drug Administration registrations of anticancer medicines for the treatment of solid tumors from the past decade were confirmed as eligible for IPD request. This quality improvement study performed a retrospective audit of the utility and completeness of the IPD and supporting documents provided from the 91 clinical trials for a planned meta-analysis.
Exposures: Request for IPD from 91 clinical oncology trials indicated as eligible for the request.
Main Outcomes and Measures: The utility and completeness of the IPD and supporting documents provided.
Results: The IPD packages were obtained from 70 of 91 requested clinical trials (77%). The median time to data provision was 123 (range, 117-352) days. Redactions were observed in 18 of the acquired IPD packages (26%) for outcome data, 11 (16%) for assessment variables, and 19 (27%) for adjustment data. Additionally, 20 IPD packages (29%) lacked a clinical study report, 4 (6%) had incomplete or missing data dictionaries, and 20 (29%) were missing anonymization or redaction description files. Access to IPD from 21 eligible trials (23%) was not granted.
Conclusions and Relevance: In this quality improvement study, there was substantial variability within the provided IPD packages regarding the completeness of key data variables and supporting documents. To improve the data sharing ecosystem, key areas for enhancement include (1) ensuring that clinical trials are eligible for IPD sharing, (2) making eligible IPD transparently accessible, and (3) ensuring that IPD packages meet a standard of utility and completeness.
| Errataetall: |
CommentOn: JAMA Oncol. 2023 Dec 1;9(12):1627-1628. - PMID 37796491 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
JAMA oncology - 9(2023), 12 vom: 01. Dez., Seite 1621-1626 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hopkins, Ashley M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print CommentOn: JAMA Oncol. 2023 Dec 1;9(12):1627-1628. - PMID 37796491 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamaoncol.2023.3996 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362902151 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362902151 | ||
| 003 | DE-627 | ||
| 005 | 20231227135906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2023.3996 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM362902151 | ||
| 035 | |a (NLM)37796495 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hopkins, Ashley M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: JAMA Oncol. 2023 Dec 1;9(12):1627-1628. - PMID 37796491 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: The pharmaceutical industry has made substantial investments in developing processes for sharing individual-participant data (IPD) from clinical trials. However, the utility and completeness of shared IPD and supporting documents must be evaluated to ensure the potential for scientific advancements from the data sharing ecosystem can be realized | ||
| 520 | |a Objective: To assess the utility and completeness of IPD and supporting documents provided from industry-sponsored clinical trials | ||
| 520 | |a Design, Setting, and Participants: From February 9, 2022, to February 9, 2023, 91 of 203 clinical trials supporting US Food and Drug Administration registrations of anticancer medicines for the treatment of solid tumors from the past decade were confirmed as eligible for IPD request. This quality improvement study performed a retrospective audit of the utility and completeness of the IPD and supporting documents provided from the 91 clinical trials for a planned meta-analysis | ||
| 520 | |a Exposures: Request for IPD from 91 clinical oncology trials indicated as eligible for the request | ||
| 520 | |a Main Outcomes and Measures: The utility and completeness of the IPD and supporting documents provided | ||
| 520 | |a Results: The IPD packages were obtained from 70 of 91 requested clinical trials (77%). The median time to data provision was 123 (range, 117-352) days. Redactions were observed in 18 of the acquired IPD packages (26%) for outcome data, 11 (16%) for assessment variables, and 19 (27%) for adjustment data. Additionally, 20 IPD packages (29%) lacked a clinical study report, 4 (6%) had incomplete or missing data dictionaries, and 20 (29%) were missing anonymization or redaction description files. Access to IPD from 21 eligible trials (23%) was not granted | ||
| 520 | |a Conclusions and Relevance: In this quality improvement study, there was substantial variability within the provided IPD packages regarding the completeness of key data variables and supporting documents. To improve the data sharing ecosystem, key areas for enhancement include (1) ensuring that clinical trials are eligible for IPD sharing, (2) making eligible IPD transparently accessible, and (3) ensuring that IPD packages meet a standard of utility and completeness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Modi, Natansh D |e verfasserin |4 aut | |
| 700 | 1 | |a Abuhelwa, Ahmad Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kichenadasse, Ganessan |e verfasserin |4 aut | |
| 700 | 1 | |a Kuderer, Nicole M |e verfasserin |4 aut | |
| 700 | 1 | |a Lyman, Gary H |e verfasserin |4 aut | |
| 700 | 1 | |a Wiese, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a McKinnon, Ross A |e verfasserin |4 aut | |
| 700 | 1 | |a Rockhold, Frank W |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Rowland, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Sorich, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d 2015 |g 9(2023), 12 vom: 01. Dez., Seite 1621-1626 |w (DE-627)NLM250070588 |x 2374-2445 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:1621-1626 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamaoncol.2023.3996 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 12 |b 01 |c 12 |h 1621-1626 | ||